Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410157 | 0.85 | JAK2 (0.43) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL24661307 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL23908895 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL15217604 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL23087948 | 0.78 | PRMT5 (0.66) | SMN1; SMN2PRMT5WDR77LMNAPARP1 | |
| SCHEMBL19746420 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL17825064 | 0.76 | PRMT5 (0.59) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL29480940 | 0.76 | PRMT5 (0.59) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA | |
| SCHEMBL23099036 | 0.76 | PRMT5 (0.59) | SMN1; SMN2PRMT5WDR77LMNAPARP1 | |
| SCHEMBL31375983 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1PRMT5WDR77LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885ALDH1A1 944/4885PRMT5 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.